Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
about
Raf-interactome in tuning the complexity and diversity of Raf function.Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer.Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancerConditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology.Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87.Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro.ATP promotes cell survival via regulation of cytosolic [Ca2+] and Bcl-2/Bax ratio in lung cancer cells.DDX3 promotes tumor invasion in colorectal cancer via the CK1ε/Dvl2 axis.Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses.Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells.Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action.EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.The Interconnections between Autophagy and Integrin-Mediated Cell Adhesion.JunD/AP-1 Antagonizes the Induction of DAPK1 To Promote the Survival of v-Src-Transformed Cells.Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma.The overexpression of PXN promotes tumor progression and leads to radioresistance in cervical cancer.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2.
P2860
Q27692653-1C032ADF-760B-4975-8D93-AEC2B3491751Q34309915-284C17F8-21E8-4294-A24E-44980039B05CQ35349490-1C11E634-7098-4C7E-99F6-220DCE51C61DQ35440276-800F8DD0-59EB-4D99-BCAC-5C9F340F5F1FQ35813685-EB3F8B68-9212-4273-8653-47BC8C169E34Q35832209-26D7F86D-D8DA-4B4E-8493-7FD2980EA32EQ36336131-4E9C9A06-F722-4527-84E4-44D1FF37099FQ36480315-570C52CB-948C-4837-9E01-1A42D3AC06E0Q36595592-07013FA4-EDAC-449D-880C-AC3B9160F356Q36939668-B90208E4-17C3-474D-86FA-4464C701D387Q37301710-D81EB210-14C7-4ADF-87AA-32A2801902DDQ37362672-97BE19D2-03AD-433F-AB5C-D54B2F8FF5ECQ37412555-24BE5E7A-AF14-446C-BB5A-8849125788EFQ37701517-5470D48A-87E4-40E3-8C1E-E40BB9CB20B1Q38806059-EC08D263-68D4-440B-9B0A-823B496C72F5Q38810052-3025E95D-EB09-4646-B88C-10DDC94FDE79Q38881938-AB56AAF7-A49D-45F2-918C-6C28CFCB9BDBQ39033614-32417ADA-3673-4BAC-B043-20FAAE61673BQ39235186-73E116CA-574A-46DC-818A-A930924F9812Q39380579-CFE81031-84A7-4AB2-B933-470D67995079Q47214718-D4B31E5C-4226-466C-8854-7A8B8322442CQ48308048-3029F690-D3D2-461F-AFB7-7E5B9DDE97B9Q54939484-EB8EC448-0BBA-4DFF-9DAB-495FA7CAB9C7Q55410765-595C2B4A-6E59-4006-B24D-72425C95A885
P2860
Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Phosphorylation of paxillin co ...... ERK-mediated Bcl-2 expression.
@en
Phosphorylation of paxillin co ...... ERK-mediated Bcl-2 expression.
@nl
type
label
Phosphorylation of paxillin co ...... ERK-mediated Bcl-2 expression.
@en
Phosphorylation of paxillin co ...... ERK-mediated Bcl-2 expression.
@nl
prefLabel
Phosphorylation of paxillin co ...... ERK-mediated Bcl-2 expression.
@en
Phosphorylation of paxillin co ...... ERK-mediated Bcl-2 expression.
@nl
P2093
P2860
P356
P1433
P1476
Phosphorylation of paxillin co ...... ERK-mediated Bcl-2 expression.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2013.389
P407
P577
2013-10-07T00:00:00Z